Cargando…
The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults. This phase IIb, observer-blind study (NCT01218113), included ART-naive HIV-1 infected adults aged 18 to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753889/ https://www.ncbi.nlm.nih.gov/pubmed/26871794 http://dx.doi.org/10.1097/MD.0000000000002673 |
_version_ | 1782415932802465792 |
---|---|
author | Dinges, Warren Girard, Pierre-Marie Podzamczer, Daniel Brockmeyer, Norbert H. García, Felipe. Harrer, Thomas Lelievre, Jean-Daniel Frank, Ian Colin De Verdière, Nathalie Yeni, Guy-Patrick Ortega Gonzalez, Enrique Rubio, Rafael Clotet Sala, Bonaventura DeJesus, Edwin Pérez-Elias, Maria Jesus Launay, Odile Pialoux, Gilles Slim, Jihad Weiss, Laurence Bouchaud, Olivier Felizarta, Franco Meurer, Anja Raffi, François Esser, Stefan Katlama, Christine Koletar, Susan L. Mounzer, Karam Swindells, Susan Baxter, John D. Schneider, Stefan Chas, Julie Molina, Jean-Michel Koutsoukos, Marguerite Collard, Alix Bourguignon, Patricia Roman, François |
author_facet | Dinges, Warren Girard, Pierre-Marie Podzamczer, Daniel Brockmeyer, Norbert H. García, Felipe. Harrer, Thomas Lelievre, Jean-Daniel Frank, Ian Colin De Verdière, Nathalie Yeni, Guy-Patrick Ortega Gonzalez, Enrique Rubio, Rafael Clotet Sala, Bonaventura DeJesus, Edwin Pérez-Elias, Maria Jesus Launay, Odile Pialoux, Gilles Slim, Jihad Weiss, Laurence Bouchaud, Olivier Felizarta, Franco Meurer, Anja Raffi, François Esser, Stefan Katlama, Christine Koletar, Susan L. Mounzer, Karam Swindells, Susan Baxter, John D. Schneider, Stefan Chas, Julie Molina, Jean-Michel Koutsoukos, Marguerite Collard, Alix Bourguignon, Patricia Roman, François |
author_sort | Dinges, Warren |
collection | PubMed |
description | The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults. This phase IIb, observer-blind study (NCT01218113), included ART-naive HIV-1 infected adults aged 18 to 55 years. Participants were randomized to receive 2 (F4/AS01(B)_2 group, N = 64) or 3 (F4/AS01(B)_3 group, N = 62) doses of F4/AS01(B) or placebo (control group, N = 64) at weeks 0, 4, and 28. Efficacy (HIV-1 VL, CD4(+) T-cell count, ART initiation, and HIV-related clinical events), safety, and immunogenicity (antibody and T-cell responses) were evaluated during 48 weeks. At week 48, based on a mixed model, no statistically significant difference in HIV-1 VL change from baseline was demonstrated between F4/AS01(B)_2 and control group (0.073 log(10) copies/mL [97.5% confidence interval (CI): −0.088; 0.235]), or F4/AS01(B)_3 and control group (−0.096 log(10) copies/mL [97.5% CI: −0.257; 0.065]). No differences between groups were observed in HIV-1 VL change, CD4(+) T-cell count, ART initiation, or HIV-related clinical events at intermediate timepoints. Among F4/AS01(B) recipients, the most frequent solicited symptoms were pain at injection site (252/300 doses), fatigue (137/300 doses), myalgia (105/300 doses), and headache (90/300 doses). Twelve serious adverse events were reported in 6 participants; 1 was considered vaccine-related (F4/AS01(B)_2 group: angioedema). F4/AS01(B) induced polyfunctional F4-specific CD4(+) T-cells, but had no significant impact on F4-specific CD8(+) T-cell and anti-F4 antibody levels. F4/AS01(B) had a clinically acceptable safety profile, induced F4-specific CD4(+) T-cell responses, but did not reduce HIV-1 VL, impact CD4(+) T-cells count, delay ART initiation, or prevent HIV-1 related clinical events. |
format | Online Article Text |
id | pubmed-4753889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-47538892016-02-26 The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial Dinges, Warren Girard, Pierre-Marie Podzamczer, Daniel Brockmeyer, Norbert H. García, Felipe. Harrer, Thomas Lelievre, Jean-Daniel Frank, Ian Colin De Verdière, Nathalie Yeni, Guy-Patrick Ortega Gonzalez, Enrique Rubio, Rafael Clotet Sala, Bonaventura DeJesus, Edwin Pérez-Elias, Maria Jesus Launay, Odile Pialoux, Gilles Slim, Jihad Weiss, Laurence Bouchaud, Olivier Felizarta, Franco Meurer, Anja Raffi, François Esser, Stefan Katlama, Christine Koletar, Susan L. Mounzer, Karam Swindells, Susan Baxter, John D. Schneider, Stefan Chas, Julie Molina, Jean-Michel Koutsoukos, Marguerite Collard, Alix Bourguignon, Patricia Roman, François Medicine (Baltimore) 4850 The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults. This phase IIb, observer-blind study (NCT01218113), included ART-naive HIV-1 infected adults aged 18 to 55 years. Participants were randomized to receive 2 (F4/AS01(B)_2 group, N = 64) or 3 (F4/AS01(B)_3 group, N = 62) doses of F4/AS01(B) or placebo (control group, N = 64) at weeks 0, 4, and 28. Efficacy (HIV-1 VL, CD4(+) T-cell count, ART initiation, and HIV-related clinical events), safety, and immunogenicity (antibody and T-cell responses) were evaluated during 48 weeks. At week 48, based on a mixed model, no statistically significant difference in HIV-1 VL change from baseline was demonstrated between F4/AS01(B)_2 and control group (0.073 log(10) copies/mL [97.5% confidence interval (CI): −0.088; 0.235]), or F4/AS01(B)_3 and control group (−0.096 log(10) copies/mL [97.5% CI: −0.257; 0.065]). No differences between groups were observed in HIV-1 VL change, CD4(+) T-cell count, ART initiation, or HIV-related clinical events at intermediate timepoints. Among F4/AS01(B) recipients, the most frequent solicited symptoms were pain at injection site (252/300 doses), fatigue (137/300 doses), myalgia (105/300 doses), and headache (90/300 doses). Twelve serious adverse events were reported in 6 participants; 1 was considered vaccine-related (F4/AS01(B)_2 group: angioedema). F4/AS01(B) induced polyfunctional F4-specific CD4(+) T-cells, but had no significant impact on F4-specific CD8(+) T-cell and anti-F4 antibody levels. F4/AS01(B) had a clinically acceptable safety profile, induced F4-specific CD4(+) T-cell responses, but did not reduce HIV-1 VL, impact CD4(+) T-cells count, delay ART initiation, or prevent HIV-1 related clinical events. Wolters Kluwer Health 2016-02-12 /pmc/articles/PMC4753889/ /pubmed/26871794 http://dx.doi.org/10.1097/MD.0000000000002673 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 4850 Dinges, Warren Girard, Pierre-Marie Podzamczer, Daniel Brockmeyer, Norbert H. García, Felipe. Harrer, Thomas Lelievre, Jean-Daniel Frank, Ian Colin De Verdière, Nathalie Yeni, Guy-Patrick Ortega Gonzalez, Enrique Rubio, Rafael Clotet Sala, Bonaventura DeJesus, Edwin Pérez-Elias, Maria Jesus Launay, Odile Pialoux, Gilles Slim, Jihad Weiss, Laurence Bouchaud, Olivier Felizarta, Franco Meurer, Anja Raffi, François Esser, Stefan Katlama, Christine Koletar, Susan L. Mounzer, Karam Swindells, Susan Baxter, John D. Schneider, Stefan Chas, Julie Molina, Jean-Michel Koutsoukos, Marguerite Collard, Alix Bourguignon, Patricia Roman, François The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title | The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title_full | The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title_fullStr | The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title_full_unstemmed | The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title_short | The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial |
title_sort | f4/as01(b) hiv-1 vaccine candidate is safe and immunogenic, but does not show viral efficacy in antiretroviral therapy-naive, hiv-1-infected adults: a randomized controlled trial |
topic | 4850 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753889/ https://www.ncbi.nlm.nih.gov/pubmed/26871794 http://dx.doi.org/10.1097/MD.0000000000002673 |
work_keys_str_mv | AT dingeswarren thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT girardpierremarie thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT podzamczerdaniel thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT brockmeyernorberth thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT garciafelipe thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT harrerthomas thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT lelievrejeandaniel thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT frankian thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT colindeverdierenathalie thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT yeniguypatrick thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT ortegagonzalezenrique thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT rubiorafael thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT clotetsalabonaventura thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT dejesusedwin thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT perezeliasmariajesus thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT launayodile thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT pialouxgilles thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT slimjihad thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT weisslaurence thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT bouchaudolivier thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT felizartafranco thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT meureranja thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT raffifrancois thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT esserstefan thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT katlamachristine thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT koletarsusanl thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT mounzerkaram thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT swindellssusan thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT baxterjohnd thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT schneiderstefan thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT chasjulie thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT molinajeanmichel thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT koutsoukosmarguerite thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT collardalix thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT bourguignonpatricia thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT romanfrancois thef4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT dingeswarren f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT girardpierremarie f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT podzamczerdaniel f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT brockmeyernorberth f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT garciafelipe f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT harrerthomas f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT lelievrejeandaniel f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT frankian f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT colindeverdierenathalie f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT yeniguypatrick f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT ortegagonzalezenrique f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT rubiorafael f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT clotetsalabonaventura f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT dejesusedwin f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT perezeliasmariajesus f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT launayodile f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT pialouxgilles f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT slimjihad f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT weisslaurence f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT bouchaudolivier f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT felizartafranco f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT meureranja f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT raffifrancois f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT esserstefan f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT katlamachristine f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT koletarsusanl f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT mounzerkaram f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT swindellssusan f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT baxterjohnd f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT schneiderstefan f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT chasjulie f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT molinajeanmichel f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT koutsoukosmarguerite f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT collardalix f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT bourguignonpatricia f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial AT romanfrancois f4as01bhiv1vaccinecandidateissafeandimmunogenicbutdoesnotshowviralefficacyinantiretroviraltherapynaivehiv1infectedadultsarandomizedcontrolledtrial |